AN EXTENSION OF BBIL/TCV/IV/2013 PHASE 4 NON-INTERFERENCE CLINICAL TRIAL IN CHILDREN WHO WERE ADMINISTERED TYPBAR TCVA CONCOMITANTLY WITH MEASLES-CONTAINING VACCINE CHILDREN AT 9 MONTHS OF AGE: TO DETERMINE THE LEVEL OF ANTI-SALMONELLA TYPHI VI POLYSACCHARIDE IGG ANTIBODIES AT THE END OF 4 YEARS AND FOLLOW UP OF A BOOSTER DOSE OF TYPBAR TCVA DOSE IN THOSE WHO HAVE LOWER OF ANTIBODIES (BELOW CORRELATE OF PROTECTION) IN HEALTHY PRIMED CHILDREN - Typbar TCV with measles vaccine
Latest Information Update: 29 Jan 2020
Price :
$35 *
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary) ; Measles virus vaccine live
- Indications Typhoid
- Focus Pharmacodynamics
- Sponsors Bharat Biotech
- 29 Jan 2020 New trial record